As the U.S. presidential election looms, a final group of medtech companies will report earnings results, setting the tone for the remainder of the year.
Masimo, with a revamped board and new interim CEO Michelle Brennan, will report results after market close today. The majority of the company’s board was nominated by Politan Capital, concluding a two-year proxy battle between the activist investor and former CEO Joe Kiani.
Baxter reports on Friday and is expected to update investors on production capacity at a key U.S. IV and dialysis solutions manufacturing site. Operations have been limited after Hurricane Helene damaged the facility. Baxter is also in the process of selling its kidney care business to Carlyle Group for $3.8 billion.
Tandem Diabetes Care and Insulet, which both make insulin pumps, will also report results this week. Insulet received an expanded indication this summer for its latest insulin pump for people with Type 2 diabetes, and Tandem is working on a pivotal study to support the use of its automated insulin delivery software for Type 2 diabetes.
Finally, Medtronic will cap off the earnings season on Nov. 19. Company leaders will likely field questions about the recent FDA approval of a new pulsed field ablation device, which could give Medtronic a competitive edge in the growing market.
Here’s a recap of our earnings coverage so far:
